メディワウンドに関するコメント

$メディワウンド(MDWD.US)$ MediWound Says FDA Accepted For Review The Supplement To The NexoBrid BLA To Include Pediatric Patients With Severe Thermal Burns

$メディワウンド(MDWD.US)$ MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army 1 MINUTE AGO, 7:00 AM EST VIA GLOBENEWSWIRE

$メディワウンド(MDWD.US)$ Dare ya!

$メディワウンド(MDWD.US)$ Existing Cash and Cash Equivalents Are Expected to Provide Sufficient Funds for the Company's Current Operating Plan Through Profitability

$メディワウンド(MDWD.US)$ reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.44) by 45.45 percent. This is a 72.73 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $4.78 million which beat the analyst consensus estimate of $4.74 million by 0.76 percent. This is a 17.70 percent decrease over sales of $5.80 million the same period last year.

$メディワウンド(MDWD.US)$ European Medicines Agency (EMA) issued a positive opinion recommending a change to the terms of the marketing authorization for NexoBrid in Europe to include all age groups for removal of eschar in patients with deep partial- and full-thickness thermal burns. The CHMP positive opinion is pending a decision by the European Commission, which is expected imminently.

$メディワウンド(MDWD.US)$ MediWound Announces A Collaboration With PolyMedics Innovations (PMI) for NexoBrid Distribution In Europe